Medivation, Inc. (MDVN)
-NasdaqGS | Prev Close: | 48.75 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | 52.00 x 400 |
|---|
| 1y Target Est: | 68.88 |
|---|
| Beta: | 1.35 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 41.52 - 59.24 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,069,280 |
|---|
| Market Cap: | 3.66B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.93 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Johnson & Johnson Gets Key Cancer Drug With Aragon BuyTheStreet(Tue, Jun 18)
- J&J to Buy Aragon for $1 BillionZacks(Tue, Jun 18)
- Medivation Voted Among Top Workplaces in the SF Bay AreaMarketwired(Tue, Jun 18)
- Movers roundup: Medivation, WeyerhaeuserAP(Mon, Jun 17)
- Johnson & Johnson And Aragon May Have Medivation Feeling Sickat Seeking Alpha(Mon, Jun 17)
- J&J to Buy Aragon Pharmaceuticals for Cancer Candidateat Bloomberg(Mon, Jun 17)
- Why Medivation Shares Retreatedat Motley Fool(Mon, Jun 17)
- J&J Rises On Aragon Acquisition; Analysts Stay Bullish On Medivationat Barrons.com(Mon, Jun 17)
- Medivation dips as J&J buys Aragon PharmaAP(Mon, Jun 17)
- Midday Movers: ERJ, UTX, MDVN & Moreat CNBC(Mon, Jun 17)
- Medivation retreats after J&J beefs up prostate cancer slateat theflyonthewall.com(Mon, Jun 17)
- J&J deal not negative for Medivation, says Citigrouptheflyonthewall.com(Mon, Jun 17)
- Medivation Stock Falls On Unusually High Volume (MDVN)at TheStreet(Mon, Jun 17)
- J&J Buy of Aragon Deals a Blow to Medivationat TheStreet(Mon, Jun 17)
- Bulls take another dose of MedivationoptionMONSTER(Thu, Jun 13)
Key Statistics
| Forward P/E (1 yr): | 77.38 |
|---|
| P/S (ttm): | 19.13 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.98 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.21 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States.
View More